FINWIRES · TerminalLIVE
FINWIRES

AXISCADES Technologies Arm Secures Order Worth INR69 Million for Mobile Mast System

By

AXISCADES Aerospace & Technologies, a wholly-owned subsidiary of AXISCADES Technologies (NSE:AXISCADES, BOM:532395), has secured an order worth 69 million Indian rupees from the Research & Development Establishment (Engineers), according to a Wednesday filing to the Indian stock exchanges.

Research & Development Establishment (Engineers) comes under the Defence Research and Development Organisation (DRDO), Ministry of Defence, India.

The contract is for the manufacturing and supply of a mobile mast system, including the manufacturing, integration, qualification testing, documentation, and delivery.

If successfully completed, the mobile mast could be deployed in other air defense systems across the country.

Related Articles

Asia

The Orissa Minerals Development Co. Names Non-Executive Chairman

The Orissa Minerals Development Co. (NSE:ORISSAMINE, BOM:590086) named M N V S Prabhakar as its new non-executive chairman, effective May 25, according to an Indian bourse filing on Tuesday.Shares of the company rose 1% in Wednesday's trade.He currently heads Rashtriya Ispat Nigam as chairman and managing director.Prabhakar succeeds Manish Raj Gupta, who held additional charge as chairman and managing director of Rashtriya Ispat Nigam, the filing said.

$BOM:590086$NSE:ORISSAMINE
Asia

Cynata Therapeutics Says Results for Phase Three Drug Candidate Study for Knee Osteoarthritis Expected in June; Shares Rise 6%

Cynata Therapeutics (ASX:CYP) said the results for the Australian phase three SCUlpTOR trial of its CYP-004 drug candidate in patients with osteoarthritis of the knee are expected in June, according to a Wednesday Australian bourse filing.The trial enrolled a total of 321 patients, who were randomized to receive either CYP-004 or placebo, with co-primary endpoints assessing change in pain and cartilage thickness, the filing said. The study database was locked, and the process of data analysis is ongoing.The results for the company's phase two trial of its CYP-001 drug candidate in adults with acute graft versus host disease are anticipated in late June or early July.A total of 65 participants were enrolled across clinical centers in Australia, the US, and Europe, randomized to receive either steroids plus CYP-001 or steroids plus placebo. The primary endpoint is overall response rate at Day 28.The company's shares rose nearly 6% in recent trading on Wednesday.

$ASX:CYP
Asia

China Merchants Securities Appoints Chairman

China Merchants Securities (HKG:6099, SHA:600999) appointed Zhu Jiangtao as chairman effective Tuesday, according to a same-day Hong Kong bourse filing.Hong Kong-listed shares of the financial firm were down 1% in Wednesday's midday trade.Zhu formally stepped down from his role as president on Tuesday to facilitate the transition.The company said it will appoint a new president as soon as practicable, with Zhu temporarily maintaining double duties during the vacancy.

$HKG:6099$SHA:600999